Compare Eli Lilly And Co (LLY) vs Southern Copper Corp (SCCO) Price & Performance

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.

LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.

Southern Copper (SCCO) trades at $198.66, down 0.95% on the day, with a bearish technical signal and mixed analyst sentiment. The company demonstrates strong fundamentals with revenue growth from $13.42B in 2025 to projected $15.8B in 2026, net income margins improving to 35.87%, and robust profitability metrics including 50.07% ROE. Recent earnings beats and a $10.2B Mexican project pipeline support long-term growth prospects, though the stock trades at premium valuations with P/E of 29.81 and P/S of 10.72.

SCCO presents a complex investment case with strong operational performance offset by valuation concerns. The upside potential lies in continued copper demand growth and project execution, while risks include premium valuation compression, commodity price volatility, and mixed Wall Street sentiment with only 10% buy ratings. Current price sits above the $165.60 consensus target, suggesting limited near-term upside despite fundamental strength.